Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 13th Annual Conference on Nephrology & Renal Care Tokyo, Japan.

Day 1 :

Keynote Forum

Thi Tuong Vy Vo

Medical Nephrologist with expertise in Paediatric Nephrology


Time : 09:30-10:20

Conference Series Nephrology Asia 2018 International Conference Keynote Speaker Thi Tuong Vy Vo photo

Dr. Vy Vo is a medical nephrologist with expertise in pediatric nephrology such as systemic lupus erythematosus, pediatric chronic kidney disease, glomerular disease. She earned his medical degree and completed her medical residency in pediatric nephrology at Medical University at Ho Chi Minh City, Viet Nam. She is interested in systemic lupus erythemosus and CKD. Working in a biggest department of pediatric dialysis of the Southern of Viet Nam, she is trying to approach patients who need to dialysis, and spend many time to treat and take care of them by her ability as well as always update new knowledge and experience from colleagues. Dr. Vy had completed some CMEs about pediatric dialysis, pediatric kidney transplatation, glomerular disease in children: challenge and update. Furthermore, in her department, she is taking part in a research about: Measuring disease activity of SLE base on SLEIDA in pediatric outpatients



Background: systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can involve many organs. In patients with SLE, there is an association of immunodysfunction due to the disease itself and immunocompromised conditions due to the use of immunosuppressive medications that put the patients susceptible to opportunistic infections. Cytomegalovirus (CMV), has been recognized in recent years to have multi-organ involvement in SLE patients. However, the screening and treatment for CMV infection in SLE patients has not been appropriately done.  Cases: we reported herein three cases of severe CMV disease in pediatric SLE patients. CMV infection was detected after SLE diagnosis, all were female from 12 to 16 years old, gastro-intestinal manifestations in two patients, proliferative nephritis in two, fever and hematologic manifestations in all patients. All patients presented a high viral load in the blood while tissue CMV found in two of three: cerebro-spinal fluid and bone marrow. Two patients received ganciclovir who fully recovered but one patient died with active CMV infection without antiviral treatment. Conclusions: This is the first report on CMV disease in SLE patients in Viet Nam, having changed our look in the management of infectious problem for these patients. 


Conference Series Nephrology Asia 2018 International Conference Keynote Speaker Punit Gupta photo

Punit Gupta, was Profossser in Government medical college hospital (consider to be the tribal of india), raipur, India. He have done bachelor degree in 2000 I.e MBBS, than master degree in General Medicine in 2003 I.e MD, than Superspeciality in Nephrology I.e DM , With PHD DEGREE . He also awarded the prestigious ISPD SCHOLARSHIP and ASN fellowship. He have awarded with APCN developmental award in Malaysia. And also awarded with many oral n poster presentation National and International. He have presented highest number of papers I.e 31 abstract in single conference under his name till date around 175 paper and abstract is presented by him in different conferences


Introduction: The literature on the clinical effectiveness of treatments for steroids resistance nephritic syndrome is very limited.mycophenolate mofetil represents a promising therapeutic alternative without nephrotoxicity. Deflazacort is a newer glucocorticoid which not  only have similar efficacy but also lower incidence of side effects compared to prednisolone. Those patients who are not responds to Deflazacort monotherapy  given Mycophenolate mofetil & these patients shows the drastic improvement with minimal relapse of the disease. This study is In order to assess whether Deflazacort &Mycophenolate mofetil adjuvant therapy can replace the traditional treatment of the nephrotic syndrome.

Method: The study was conducted in the Department of Medicine, Pt. J.N.M. Medical College and Dr. B.R.A.M.Hospital, Raipur. 55 patients of Nephrotic Syndrome were included for the purpose of study admitted in Nephrology Unit, Pt.J.N.M.Medical College Raipur from was studied. All patients were subjected to routine investigations, Thyroid Function Test, CBC etc.


  • Total no of patients included in study are 55.
  • Mean age of the patient is 28.25±13.03 years.
  • 66.66%patients are Male while 33.33% patients are female.
  • Number of patient Steroid Dependent Nephrotic Syndrome patient are 25%
  • Number of patient Steroid Resistant Nephrotic Syndrome patient are 75%
  • 95.83% patients having Hypoalbuminea.
  • 41.66% patients are Hypothyroid out of them 70% was male & 30 % was female.
  • 95.83% patients shows electrolyte imbalance.
  • 91.66% patients shows abnormal usg findings in which increased Echotexture, Ascites, Plural Effusion & Follicular Cyst seen in 62.5%, 45.83%, 41.66% & 8.31% respectively.
  • Average weight of the Nephrotic Syndrome patient is 51.33±16.31kg
  • Dose of Deflazacort used is 1 mg/kg body weight.
  • Dose of Mycophenolate mofetil used is 12mg/kg body weight.
  • Average weight reduction in week duration is 8.083±3.88 kg
  • 12 % patient developed complication of nephrotic syndrome specially DVT.
  • Only 4 patients shows complication of mycophenolate mofetil in the form of loose stool and low WBC count .
  • 96% patients shows improvement in 6 month follow up & only 1 patient had relapse because of irregular medication.


  • Male shows greater improvement than female.
  • Maximum weight reduction was from 96 kg to 54 kg at the time of discharge
  • Hypoalbuminemia and hypothyroidism was common in male than female.
  • Loose stool and low WBC count as common complication with Mycophenolate mofetil.
  • 96% patients shows improvement with Deflazacort &Mycophenolate mofetil.


Keynote Forum

Tracy Mcgregor

Tracy McGregor, Alnylam Pharmaceuticals, Cambridge, MA, United States

Keynote: A Phase 1/2 Trial of Lumasiran, an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1

Time : 9:30am

Conference Series Nephrology Asia 2018 International Conference Keynote Speaker Tracy Mcgregor photo

Dr. Tracy McGregor joined Alnylam Pharmaceuticals as Director of Clinical Research in 2016 where she serves as the medical lead for the lumasiran (formerly ALN-GO1) program, an investigational RNAi therapeutic for the potential treatment of Primary Hyperoxaluria, Type 1. Previously, she was Vanderbilt University Medical Center as a Clinical Geneticist at. She trained in Pediatrics and Clinical Genetics at St. Louis Children’s Hospital, and holds board certification in both. Dr. McGregor obtained her medical degree at Washington University in St. Louis and her Master of Science in Clinical Investigation at Vanderbilt. 


In Primary Hyperoxaluria Type 1 (PH1), alanine-glyoxylate aminotransferase deficiency leads to excessive hepatic oxalate production, resulting in progressive renal impairment and multi-organ damage from systemic oxalosis. Lumasiran (ALN-GO1) is an investigational RNA interference (RNAi) therapeutic which suppresses hepatic glycolate oxidase, decreasing the conversion of glycolate to glyoxylate, a required substrate for oxalate production. Data from healthy adult volunteers showed that single-dose lumasiran was well tolerated with dose-dependent elevations in plasma glycolate. Here we report initial data from patients with PH1 in Phase 2 of the ALN-GO1001 study.  
The Phase 2 is a randomized, placebo controlled, single-blind, multicenter trial in patients with PH1 with urinary oxalate ≥0.7 mmol/24h/1.73m2 and eGFR >45 ml/min/1.73m2. One of four patients in each cohort is randomized to receive 3 doses of placebo prior to lumasiran dosing. The first cohort received 1 mg/kg lumasiran subcutaneously every 28 days x 3 doses; the second cohort received 3 mg/kg lumasiran. The primary endpoint is safety, and secondary endpoints include change in 24hour urinary oxalate from baseline.  
Lumasiran has demonstrated acceptable preliminary safety and tolerability with no treatment related serious adverse events or discontinuations from study. Initial results revealed all three patients randomized to lumasiran in the first cohort experienced >50% decrease in urinary oxalate from baseline. The patient randomized to placebo was subsequently given lumasiran 1 mg/kg monthly for three months, and experienced similar reduction in urinary oxalate. [Figure 1] All patients treated with lumasiran experienced a lowering of urinary oxalate below 1.1 mmol/24hrs/1.73m2 – a threshold associated with reduced progression to end-stage renal disease. Data from the second cohort will be presented.  
Preliminary data show promising activity in lowering urinary oxalate in patients with PH1 and support development of lumasiran as a potential therapeutic approach to alleviate pathologic overproduction of oxalate in this devastating disease.